

Edgar Filing: AMARIN CORP PLC\UK - Form 6-K

AMARIN CORP PLC\UK
Form 6-K
August 19, 2002

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUERS PURSUANT TO RULE
13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT
OF 1934

Dated: August 19, 2002

Commission file number 0-21392

AMARIN CORPORATION PLC
(Exact name of Registrant as Specified in its Charter)

ENGLAND
(Jurisdiction of Incorporation or
organization of Issuer)

7 Curzon Street
London W1J 5HG, England
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or
Form 40-F.

☒ Form 20-F ☐ Form 40-F

Indicate by check mark whether the registrant by
furnishing the information contained in this Form is
also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

☐ Yes ☒ No

Attachment:

Material Events

(a) Amarin Corporation plc appoints Stefan V. Ohlsson as Managing Director of
Amarin Development AB.

This report on Form 6-K is hereby incorporated
by reference in the registration statement on Form F-3
(Registration Statement No. 333-12642) of Amarin
Corporation plc and in the prospectus contained therein,
and in the Registration Statement on Form F-3
(Registration No. 333-13200) of Amarin Corporation plc
and in the prospectus contained therein, and this report
on Form 6-K shall be deemed a part of each such
registration statement from the date on which this
report is filed, to the extent not superseded by

Edgar Filing: AMARIN CORP PLC\UK - Form 6-K

documents or reports subsequently filed.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMARIN CORPORATION PLC

By:/s/Richard A B Stewart
Richard A B Stewart
Chief Executive Officer

Date: August 19, 2002

Exhibits	Index to
Exhibit Item	Sequentially Numbered Page
(a) Material Event description- Amarin Corporation plc appoints Stefan V. Ohlsson as Managing Director of Amarin Development AB	4

(a)

Exhibit

Edgar Filing: AMARIN CORP PLC\UK - Form 6-K

Contacts:

Rick Stewart	Stefan Ohlsson
Chief Executive Officer	Managing Director
Amarin Corporation plc	Amarin Development AB
Phone: +44 (0) 207 907 2440	Phone: +46 (0)40 53 98 01
Email: rick.stewart@amarincorp.com	Email: Stefan.ohlsson@amarindev.se

AMARIN CORPORATION PLC APPOINTS STEFAN OHLSSON MANAGING
DIRECTOR OF AMARIN DEVELOPMENT AB

LONDON, United Kingdom, August 19, 2002 Amarin Corporation plc
NASDAQ - AMRN) today announced the appointment of Stefan V.
Ohlsson as Managing Director of Amarin Development AB
effective immediately. Mr. Ohlsson will be based at Amarin
Development AB's headquarters in Malmo, Sweden.

Mr. Ohlsson has extensive experience in the pharmaceutical
industry, including development, marketing and project
management. His most recent position was with AstraZeneca
as a Global Development Director.

"Amarin Development AB is increasingly recognised as a leader
in the field of product development. Stefan's experience and
capabilities will accelerate the growth of Amarin Development
and provide further focus on achieving our goals. The recently
announced strategic technology collaborations will also benefit
from Stefan's expertise. We very much welcome Stefan to the
Amarin team", commented Richard Stewart, CEO of Amarin Corporation.

Amarin Corporation plc is a specialty pharmaceutical company
focused on neurology and pain management. The Company plans to
become a leader in these therapeutic categories by providing
innovative products and solutions that address significant unmet
medical needs. For press releases and other corporate information,
visit our website at <http://www.amarincorp.com>.

Statements in this press release that are not historical facts are
forward-looking statements that involve risks and uncertainties
which may cause the Company's actual results in future periods to be
materially different from any performance suggested herein. Such
risks and uncertainties include, without limitation, risks
associated with the inherent uncertainty of pharmaceutical research,
product development and commercialisation, the impact of competitive
products and patents, as well as other risks and uncertainties
detailed from time to time in periodic reports. For more
information, please refer to Amarin Corporation's Annual Report for
2001 on Form 20-F and its Form 6-Ks as filed with the U.S.
Securities and Exchange Commission. The Company assumes no
obligation to update information on its expectations.